APA (7th ed.) Citation

Sikiric, P., Barisic, I., Udovicic, M., Lovric Bencic, M., Balenovic, D., Strinic, D., . . . Tvrdeic, A. (2026). Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias. Pharmaceuticals (14248247), 19(2), 235. https://doi.org/10.3390/ph19020235

Chicago Style (17th ed.) Citation

Sikiric, Predrag, et al. "Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias." Pharmaceuticals (14248247) 19, no. 2 (2026): 235. https://doi.org/10.3390/ph19020235.

MLA (9th ed.) Citation

Sikiric, Predrag, et al. "Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias." Pharmaceuticals (14248247), vol. 19, no. 2, 2026, p. 235, https://doi.org/10.3390/ph19020235.